Table 1.
Cancer Type | 1995-1999 | 2000-2004 | ||||
---|---|---|---|---|---|---|
| ||||||
SEP 1c | SEP 5d | SRR (95% CI)e | SEP 1c | SEP 5d | SRR (95% CI)e | |
All sites | 306.5 | 350.9 | 0.87 (0.83-0.91) | 299.9 | 332.8 | 0.90 (0.86-0.94) |
Brain and other nervous system | 4.1 | 5.1 | 0.79 (0.52-1.18) | 3.8 | 3.6 | 1.05 (0.68-1.56) |
Colon and rectum | 31.2 | 41.9 | 0.74 (0.64-0.85) | 32.5 | 42.6 | 0.76 (0.66-0.87) |
Esophagus | 11.5 | 7.9 | 1.45 (1.11-1.87) | 10.2 | 6.6 | 1.54 (1.18-1.99) |
Kidney and renal pelvis | 3.8 | 7.1 | 0.53 (0.34-0.80) | 4.3 | 7.6 | 0.56 (0.38-0.81) |
Larynx | 8.3 | 8.8 | 0.94 (0.69-1.25) | 7.8 | 6.3 | 1.25 (0.92-1.66) |
Leukemia | 6.8 | 8.6 | 0.79 (0.57-1.07) | 6.7 | 7.3 | 0.91 (0.66-1.22) |
Liver and intrahepatic bile duct | 6.6 | 10.7 | 0.61 (0.44-0.83) | 7.1 | 11.0 | 0.64 (0.47-0.86) |
Lung and bronchus | 25.1 | 27.5 | 0.91 (0.77-1.07) | 19.4 | 24.1 | 0.80 (0.67-0.95) |
Non-Hodgkin lymphoma | 9.7 | 12.2 | 0.79 (0.60-1.02) | 7.9 | 11.9 | 0.66 (0.49-0.86) |
Oral cavity and pharynx | 18.1 | 17.8 | 1.01 (0.83-1.23) | 14.7 | 13.9 | 1.05 (0.85-1.29) |
Pancreas | 6.6 | 6.7 | 0.98 (0.69-1.35) | 4.8 | 6.3 | 0.75 (0.51-1.06) |
Penis | 4.0 | 2.3 | 1.74 (1.09-2.71) | 2.6 | 1.5 | 1.69 (0.96-2.87) |
Prostate | 101.3 | 128.7 | 0.78 (0.72-0.85) | 114.4 | 128.8 | 0.88 (0.82-0.95) |
Stomach | 26.3 | 13.3 | 1.97 (1.64-2.35) | 17.2 | 11.1 | 1.54 (1.26-1.89) |
Thyroid | NCf | NCf | NCf | 2.1 | 2.7 | 0.77 (0.43-1.30) |
Urinary bladder | 11.8 | 12.4 | 0.94 (0.73-1.20) | 11.3 | 11.6 | 0.97 (0.76-1.23) |
Abbreviations: SRR, standardized rate ratio; CI, confidence interval; NC, not calculated.
Rates are per 100,000 and are age-adjusted to the Census 2000 population for Puerto Rico (12).
See Methods for calculations used to derive SEP scores.
SEP 1 is the lowest socioeconomic position.
SEP 5 is the highest socioeconomic position and is the reference group.
Defined as SEP 1 divided by SEP 5 according to the Tiwari method.
Cell contains <15 cases in 1 of the categories.